Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions

@inproceedings{Bienkowski2015ClinicalNP,
  title={Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions },
  author={Michal Bienkowski and Anna Sophie Berghoff and Christine Marosi and Adelheid Woehrer and Harald Heinzl and Johannes Andreas Hainfellner and Matthias Preusser},
  booktitle={Clinical neuropathology},
  year={2015}
}
O6-methylguanine-methyltransferase (MGMT) promoter methylation status has prognostic and, in the subpopulation of elderly patients, predictive value in newly diagnosed glioblastoma. Therefore, knowledge of the MGMT promoter methylation status is important for clinical decision-making. So far, MGMT testing has been limited by the lack of a robust test with sufficiently high analytical performance. Recently, one of several available pyrosequencing protocols has been shown to be an accurate and… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.

International journal of clinical and experimental pathology • 2015
View 6 Excerpts
Highly Influenced

MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.

The International journal of biological markers • 2015
View 8 Excerpts
Highly Influenced

Prognosis of glioblastoma with faint MGMT methylation-specific PCR product

Journal of Neuro-Oncology • 2014
View 7 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…